کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
1902385 | 1045742 | 2011 | 11 صفحه PDF | دانلود رایگان |
Mesenchymal stem cells (MSCs) are multi-potent adult stem cells harboring multi-lineage differentiation potential and immunosuppressive properties that make MSCs an ideal candidate cell type for immunomodulation and regenerative medicine. Currently, MSC-related researches and clinical trials have evoked exciting promise in a variety of disorders and tissue regeneration. However, it must be recognized that several critical potential problems have also emerged from current clinical trials, for example: (1) the indefinite association between the phenotypic characteristics and the biological functions of MSCs; (2) the lack of clinical data to support the long-term safety of MSCs; (3) the need for further clarification of multiple mechanisms of MSC transplant actions in vivo; and (4) the lack of comparability of MSC transplant efficacy. Therefore, MSC-based therapies could not yet be considered a routine treatment in the clinic. Based on these, we proposed that large-scale and multi-center clinical trials of MSC-based therapies should be initiated under strict supervision. These interventions might help to establish a new clinical paradigm to turn MSC transplantation into a routine therapy for at least some diseases in the near future.
Research highlights▶ MSCs possess the potential of multi-lineage differentiation and immunosuppression. ▶ MSCs can serve as an ideal candidate for immunomodulation and regenerative medicine. ▶ MSC-based therapies in various diseases have generated great excitement. ▶ The potential barriers will not stamp MSC-based clinical therapies.
Journal: Ageing Research Reviews - Volume 10, Issue 1, January 2011, Pages 93–103